Literature DB >> 15126644

Cardiac transcriptional response to acute and chronic angiotensin II treatments.

Jennie E Larkin1, Bryan C Frank, Renee M Gaspard, Irena Duka, Haralambos Gavras, John Quackenbush.   

Abstract

Exposure of experimental animals to increased angiotensin II (ANG II) induces hypertension associated with cardiac hypertrophy, inflammation, and myocardial necrosis and fibrosis. Some of the most effective antihypertensive treatments are those that antagonize ANG II. We investigated cardiac gene expression in response to acute (24 h) and chronic (14 day) infusion of ANG II in mice; 24-h treatment induces hypertension, and 14-day treatment induces hypertension and extensive cardiac hypertrophy and necrosis. For genes differentially expressed in response to ANG II treatment, we tested for significant regulation of pathways, based on Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Microarray Pathway Profiler (GenMAPP) databases, as well as functional classes based on Gene Ontology (GO) terms. Both acute and chronic ANG II treatments resulted in decreased expression of mitochondrial metabolic genes, notably those for the electron transport chain and Krebs-TCA cycle; chronic ANG II treatment also resulted in decreased expression of genes involved in fatty acid metabolism. In contrast, genes involved in protein translation and ribosomal activity increased expression following both acute and chronic ANG II treatments. Some classes of genes showed differential response between acute and chronic ANG II treatments. Acute treatment increased expression of genes involved in oxidative stress and amino acid metabolism, whereas chronic treatments increased cytoskeletal and extracellular matrix genes, second messenger cascades responsive to ANG II, and amyloidosis genes. Although a functional linkage between Alzheimer disease, hypertension, and high cholesterol has been previously documented in studies of brain tissue, this is the first demonstration of induction of Alzheimer disease pathways by hypertension in heart tissue. This study provides the most comprehensive available survey of gene expression changes in response to acute and chronic ANG II treatment, verifying results from disparate studies, and suggests mechanisms that provide novel insight into the etiology of hypertensive heart disease and possible therapeutic interventions that may help to mitigate its effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126644     DOI: 10.1152/physiolgenomics.00057.2004

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  23 in total

Review 1.  Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress.

Authors:  León Ferder; Felipe Inserra; Manuel Martínez-Maldonado
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

2.  Global transcription profiling reveals comprehensive insights into hypoxic response in Arabidopsis.

Authors:  Fenglong Liu; Tara Vantoai; Linda P Moy; Geoffrey Bock; Lara D Linford; John Quackenbush
Journal:  Plant Physiol       Date:  2005-02-25       Impact factor: 8.340

3.  Blockade of endogenous angiotensin II type I receptor agonistic autoantibody activity improves mitochondrial reactive oxygen species and hypertension in a rat model of preeclampsia.

Authors:  Venkata Ramana Vaka; Mark W Cunningham; Evangeline Deer; Michael Franks; Tarek Ibrahim; Lorena M Amaral; Nathan Usry; Denise C Cornelius; Ralf Dechend; Gerd Wallukat; Babbette D LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-11-13       Impact factor: 3.619

4.  Protein kinase C (PKC)ζ-mediated Gαq stimulation of ERK5 protein pathway in cardiomyocytes and cardiac fibroblasts.

Authors:  Carlota García-Hoz; Guzmán Sánchez-Fernández; Ramón García-Escudero; María Fernández-Velasco; Julia Palacios-García; Marisol Ruiz-Meana; Maria Teresa Díaz-Meco; Michael Leitges; Jorge Moscat; David García-Dorado; Lisardo Boscá; Federico Mayor; Catalina Ribas
Journal:  J Biol Chem       Date:  2012-01-09       Impact factor: 5.157

Review 5.  New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II.

Authors:  Jia L Zhuo; Xiao C Li
Journal:  Peptides       Date:  2011-06-14       Impact factor: 3.750

6.  Limiting angiotensin II signaling with a cell-penetrating peptide mimicking the second intracellular loop of the angiotensin II type-I receptor.

Authors:  Jun Yu; Linda Taylor; Dale Mierke; Eric Berg; Michael Shia; Jordan Fishman; Christine Sallum; Peter Polgar
Journal:  Chem Biol Drug Des       Date:  2010-05-18       Impact factor: 2.817

7.  Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion.

Authors:  Yong Seon Choi; Ana Barbosa Marcondes de Mattos; Dan Shao; Tao Li; Miranda Nabben; Maengjo Kim; Wang Wang; Rong Tian; Stephen C Kolwicz
Journal:  J Mol Cell Cardiol       Date:  2016-09-28       Impact factor: 5.000

8.  Renin-angiotensin system inhibitors protect against age-related changes in rat liver mitochondrial DNA content and gene expression.

Authors:  Elena M V de Cavanagh; Idhaliz Flores; Marcelo Ferder; Felipe Inserra; León Ferder
Journal:  Exp Gerontol       Date:  2008-08-15       Impact factor: 4.032

9.  Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2.

Authors:  Sarah A McCalmon; Danielle M Desjardins; Saad Ahmad; Katharine S Davidoff; Christine M Snyder; Kaori Sato; Koji Ohashi; Ondra M Kielbasa; Matthen Mathew; Elizabeth P Ewen; Kenneth Walsh; Haralambos Gavras; Francisco J Naya
Journal:  Circ Res       Date:  2010-01-21       Impact factor: 17.367

10.  Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice.

Authors:  Adrienn Kis; Colin Murdoch; Min Zhang; Anjana Siva; Sergio Rodriguez-Cuenca; Stefania Carobbio; Agnes Lukasik; Margaret Blount; Steve O'Rahilly; Sarah L Gray; Ajay M Shah; Antonio Vidal-Puig
Journal:  Eur J Heart Fail       Date:  2009-04-24       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.